Reviewing WuXi AppTec (OTCMKTS:WUXAY) and OPKO Health (NASDAQ:OPK)
OPKO Health (NASDAQ:OPK – Get Free Report) and WuXi AppTec (OTCMKTS:WUXAY – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership. Valuation & Earnings This table compares OPKO Health […] OPKO Health (NASDAQ:OPK) and WuXi AppTec (OTCMKTS:WUXAY) are both medical companies, but which is the superior investment? This article compares the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership. OPKO Health has a consensus price target of $3.85, suggesting a potential upside of 191.67%. WuXiappTec has lower revenue, but higher earnings than OPKO health, and its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with type 2 diabetes and related obesity. OP KO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, Wuxi Biology, Wu Xi ATU, WuXXi DDSU, and Others.
发表 : 2年前 经过 Defense World Staff 在 Finance
OPKO Health (NASDAQ:OPK – Get Free Report) and WuXi AppTec (OTCMKTS:WUXAY – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.
This table compares OPKO Health and WuXi AppTec’s revenue, earnings per share (EPS) and valuation.
WuXi AppTec has lower revenue, but higher earnings than OPKO Health.
This is a breakdown of recent ratings for OPKO Health and WuXi AppTec, as reported by MarketBeat.
OPKO Health currently has a consensus price target of $3.85, suggesting a potential upside of 191.67%. Given OPKO Health’s higher probable upside, analysts clearly believe OPKO Health is more favorable than WuXi AppTec.
This table compares OPKO Health and WuXi AppTec’s net margins, return on equity and return on assets.
OPKO Health beats WuXi AppTec on 5 of the 8 factors compared between the two stocks.
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical testing services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
话题: Markets, NASDAQ